Evidence map›Paper›PMID 39639042›Full record

ArticleScientific reports2024

Clinical and prognostic effects of microvascular density and FOXP3 positive T cells in breast cancer.

Yaşar Culha, Cigdem Ozdemir, Sena Ece Davarci, Beyza Ünlü, Mehmet Olgun A K, Hacer Demir, Meltem Baykara

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. The influence of diabetes mellitus on blood vessels' amounts and immune status in case of breast cancer.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yaşar CulhaDepartment of Medical Oncology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey. drjasar@hotmail.com.ORCID 0000-0002-0317-7552
Cigdem OzdemirDepartment of Pathology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0001-8500-0744
Sena Ece DavarciDepartment of Medical Oncology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0003-1142-9411
Beyza ÜnlüDepartment of Medical Oncology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0002-8178-0277
Mehmet Olgun A KDepartment of Pathology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0003-1845-1849
Hacer DemirDepartment of Medical Oncology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0003-1235-9363
Meltem BaykaraDepartment of Medical Oncology, Afyonkarahisar Health Sciences University School of Medicine, Afyonkarahisar, Turkey.ORCID 0000-0003-3291-8134

Funding

This study was supported by Afyonkarahisar Health Sciences University Scientific Research Projects Coordination 20.GENEL.020
6 · The paper itself

Abstract

There are conflicting data regarding the prognostic effect of microvascular density (MVD) in breast cancer and its molecular subtypes. It is thought that high levels of FOXP3 + T cells in breast cancer are associated with poor prognosis. However, data regarding FOXP3 show significant variability in the literature. In our study, we aim to measure MVD and FOXP3 + T cells in breast cancer cases and investigate their relationship with each other and their effects on breast cancer patients' clinical and prognostic features. In our study, the results of 207 female breast cancer patients whose excisional tumoral tissue was obtained are presented. The study evaluated the findings under a light microscope using antibodies against CD34 for measuring MVD and FOXP3 for measuring FOXP3-positive T cells. CD34 ≥ 17 was categorized as high MVD, and CD34 < 17 was classified as low MVD. FOXP3 + cell count ≥ 20/mm2 was categorized as high FOXP3 positivity and < 20/mm2 as low FOXP3 positivity. The SPSS program (version 22) was used to evaluate the results statistically, and p < 0.05 was considered significant. The median age was 54.0 (27-86) years, and the median follow-up period was 60.0 (IQR: 42.6-86.5) months. In the high MVD group, a higher progesterone receptor (PR) positivity rate was detected (p = 0.035). High FOXP3 positivity was significantly associated with high nuclear grade (p = 0.003). High FOXP3 positivity was significantly associated with PR negativity and high Ki67 values ​​(p = 0.009, p = 0.012, respectively). No statistically significant correlation was found between MVD elevation and FOXP3 positivity (r = 0.063, p = 0.36). A weakly significant positive correlation was detected between high Ki67 and FOXP3 positivity (r = 0.0146, p = 0.04). A weak inverse correlation was detected between high FOXP3 positivity and PR percentage values ​​(r=-0.182, p = 0.01). While there was no significant difference in disease-free survival in cases with high MVD and high FOXP3 + T cells compared to groups with low levels, the results were not mature enough because the median values ​​in overall survival could not be reached. A significant correlation was found between high FOXP3 positivity and some aggressive tumor features; no effect on survival was detected. In contrast to literature data on luminal A breast cancer, high MVD in the luminal B (HER2-) subgroup was associated with a lower risk of recurrence. Our study is the first in the literature to evaluate the relationship between MVD measured using CD34 and FOXP3 positive T cells in breast cancer. Our study found no correlation between MVD and FOXP3 positivity, while literature data show significant correlations in some other cancers.

Indexed as

Breast NeoplasmsForkhead Transcription FactorsMicrovascular DensityAdultAgedAged, 80 and overFemaleHumansMiddle AgedPrognosisT-LymphocytesT-Lymphocytes, RegulatoryForkhead Transcription FactorsFOXP3 protein, humanBreast cancerCD34FOXP3 T cellsMicrovascular density

Identifiers

PMID39639042
PMCPMC11621116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.